Home › VYTORIN (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
 

Keywords :   


VYTORIN (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study

2014-11-17 17:45:00| Merck.com - Product News

Dateline City: CHICAGO CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the events study reduced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Farm Progress America, May 20, 2024
20.05Farm Progress America, May 20, 2024
20.05Nielsen launches The Media Distributor Gauge
20.05Minerva AI Companion enhances the TV viewing experience
20.05Ryanair profits surge after fares climb by 20%
20.05SES Ethiosat delivering content to 95% of TV homes in Ethiopia
20.05Vidzemes TV expands with PlayBox Neo Channel-in-a-Box playout
20.05ocilion enhances user experience with Simply.TV metadata
More »